Medical devices, healthcare technology and the business of care
PMA approval · P130016

NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM

Cochlear Americas · Decision date Mar 20, 2014

FDA DECISIONP130016

What did the FDA approve?

FDA records P130016 as an original PMA application. The recorded decision is approval, dated Mar 20, 2014.

FDA approval order statement

APPROVAL FOR THE NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM. THE NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM IS INTENDED TO PROVIDE ELECTRIC STIMULATION TO THE MID-TO-HIGH FREQUENCY REGION OF THE COCHLEA AND ACOUSTIC AMPLIFICATION TO THE LOW FREQUENCY REGIONS, FOR PATIENTS WITH RESIDUAL LOW FREQUENCY HEARING SENSITIVITY. THE SYSTEM IS INDICATED FOR UNILATERAL USE IN PATIENTS AGED 18 YEARS AND OLDER WHO HAVE RESIDUALLOW-FREQUENCY HEARING SENSITIVITY AND SEVERE TO PROFOUND HIGH FREQUENCY SENSORINEURAL HEARING LOSS, AND WHO OBTAIN LIMITED BENEFIT FROM APPROPRIATELY FIT BILATERAL HEARING AIDS. TYPICAL PREOPERATIVE HEARING OF CANDIDATES RANGES FROM NORMAL TO MODERATE HEARING LOSS IN THE LOW FREQUENCIES (THRESHOLDS NO POORER THAN 60 DB HL UP TO AND INCLUDING 500 HZ), WITH SEVERE TO PROFOUND MID TO HIGH FREQUENCY HEARING LOSS (THRESHOLD AVERAGE OF 2000, 3000, AND 4000 HZ >=75 DB HL) IN THE EAR TO BE IMPLANTED, AND MODERATELY SEVERE TO PROFOUND MID TO HIGH FREQUENCY HEARING LOSS (THRESHOLD AVERAGE OF 2000, 3000, AND 4000 HZ >=60 DB HL) IN THE CONTRALATERAL EAR. THE CNC WORD RECOGNITION SCORE WILL BE BETWEEN 10% AND 60%, INCLUSIVELY, IN THE EAR TO BE IMPLANTED IN THE PREOPERATIVE AIDED CONDITION AND IN THE CONTRALATERAL EAR WILL BE EQUAL TO OR BETTER THAN THAT OF THE EAR TO BE IMPLANTED BUT NOT MORE THAN 80% CORRECT. PROSPECTIVE CANDIDATES SHOULDGO THROUGH A SUITABLE HEARING AID TRIAL, UNLESS ALREADY APPROPRIATELY FIT WITH HEARING AIDS.
Regulatory pathway
Original PMA
Clinical specialty
Ear, Nose, Throat
Decision date
Mar 20, 2014

FDA source record

Regulatory record facts

Identifier
P130016
Regulatory pathway
Premarket approval application
Product code
PGQ
Decision code
APPR
Decision date
Mar 20, 2014
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cochlear implant with combined electrical stimulation and acoustic amplification.

Product code
PGQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P130016 received

    Application receipt date recorded by FDA.

  2. P130016 · FDA decision

    APPR

  3. P130016/S061 · Related supplement

    Cochlear Hybrid Implant System

Timeline entries are records held by MedtechLedger for P130016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130016

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cochlear Americas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10350 Park Meadows Dr., Lone Tree, CO, 80124

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records